Primary Causes of Death in Patients with Non-Hodgkin’s Lymphoma: A Retrospective Cohort Study

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-64356926980727
   PubMed Web of Science ®Google Scholar
• Chiu BCH, Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res. 2015;165:1–25. doi:10.1007/978-3-319-13150-4_125655604
   PubMedGoogle Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Kamel MG, Elqushayri AE, Thach TQ, Huy NT. Cardiovascular mortality trends in non-Hodgkin’s lymphoma: a population-based cohort study. Expert Rev Anticancer Ther. 2018;18(1):91–100. doi:10.1080/14737140.2018.140962629192533
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):115. doi:10.1186/s13045-019-0785-731744509
   PubMed Web of Science ®Google Scholar
• Bluhm EC, Ronckers C, Hayashi RJ, et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(8):4014–4021. doi:10.1182/blood-2007-08-10602118258798
   PubMed Web of Science ®Google Scholar
• Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848–857. doi:10.1016/S0140-6736(12)60605-922835603
   PubMed Web of Science ®Google Scholar
• Aviles A, Delgado S, Fernandez R, Talavera A, Neri N, Huerta-Guzman J. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol. 2002;68(3):144–149. doi:10.1034/j.1600-0609.2002.01542.x12068794
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545. doi:10.1056/NEJM1995120733323057477169
   PubMed Web of Science ®Google Scholar
• Project IN-HsLPF. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM1993093032914028141877
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144
   Web of Science ®Google Scholar
• Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388–1395. doi:10.1038/bmt.2009.35920062101
   PubMed Web of Science ®Google Scholar
• Kim SJ, Choi CW, Mun YC, et al. Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer. 2011;11:321. doi:10.1186/1471-2407-11-32121798075
   PubMed Web of Science ®Google Scholar
• Găman AM. Follicular non-Hodgkin’s lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival. Rom J Morphol Embryol. 2013;54(1):71–76.23529311
   PubMed Web of Science ®Google Scholar
• Găman A, Bold A, Găman G. The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma. Rom J Morphol Embryol. 2011;52(2):719–722.21655667
   PubMed Web of Science ®Google Scholar
• Subramanian J, Cavenagh J, Desai B, Jacobs I. Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape. Cancer Manag Res. 2017;9:131–140. doi:10.2147/CMAR.S12058928479860
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res. 1993;53(9):2118–2122.8481913
   PubMed Web of Science ®Google Scholar
• Dehghani M, Haddadi S, Vojdani R. Signs, Symptoms and Complications of Non-Hodgkin’s Lymphoma According to Grade and Stage in South Iran. Asian Pac J Cancer Prev. 2015;16(8):3551–3557. doi:10.7314/APJCP.2015.16.8.355125921177
   PubMedGoogle Scholar
• Patel A, Sharma MC, Mallick S, Patel M, Bakhshi S. Poor performance status, urban residence and female sex predict inferior survival in pediatric advanced stage mature B-NHL in an Indian tertiary care center. Pediatr Hematol Oncol. 2018;35(1):23–32. doi:10.1080/08880018.2018.142427929388861
   PubMed Web of Science ®Google Scholar
• Wang YG, Zhao LY, Liu CQ, et al. Clinical characteristics and prognostic factors of primary gastric lymphoma: a retrospective study with 165 cases. Medicine (Baltimore). 2016;95(31):e4250. doi:10.1097/MD.000000000000425027495029
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–407. doi:10.1093/annonc/mdw60427831506
   PubMed Web of Science ®Google Scholar
• Vakeva L, Lipsanen T, Sintonen H, Ranki A. Morbidity and causes of death in patients with cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2017;97(6):735–738. doi:10.2340/00015555-262928175924
   PubMed Web of Science ®Google Scholar
• Mei M, Wang Y, Zhang M. Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: a cohort study. PLoS One. 2019;14(4):e0214860. doi:10.1371/journal.pone.021486030995261
   PubMed Web of Science ®Google Scholar
• Boyne DJ, Mickle AT, Brenner DR, et al. Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis. Cancer Med. 2018;7(9):4801–4813. doi:10.1002/cam4.157230112841
   PubMed Web of Science ®Google Scholar
• Abuamsha H, Kadri AN, Hernandez AV. Cardiovascular mortality among patients with non-Hodgkin lymphoma: differences according to lymphoma subtype. Hematol Oncol. 2019;37(3):261–269. doi:10.1002/hon.260730916804
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Zhang Q, Kocherginsky MN. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301–2308. doi:10.1158/1078-0432.CCR-11-209722282466
   PubMed Web of Science ®Google Scholar
• Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92(7):706–715. doi:10.1002/ajh.2479128516671
   PubMed Web of Science ®Google Scholar